Biotron Valuation
Is BIT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BIT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BIT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIT?
Other financial metrics that can be useful for relative valuation.
| What is BIT's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | AU$64.06m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 38.5x |
| Enterprise Value/EBITDA | -15.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BIT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 19.6x | ||
BTG Beroni Group | 39.8x | n/a | AU$75.9m |
ACW Actinogen Medical | 14.1x | 97.7% | AU$69.8m |
PTX Prescient Therapeutics | 15.3x | n/a | AU$49.9m |
ATH Alterity Therapeutics | 9.2x | -30.9% | AU$26.2m |
BIT Biotron | 38.4x | n/a | AU$64.1m |
Price-To-Sales vs Peers: BIT is expensive based on its Price-To-Sales Ratio (38.4x) compared to the peer average (12.8x).
Price to Earnings Ratio vs Industry
How does BIT's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales vs Industry: BIT is expensive based on its Price-To-Sales Ratio (38.4x) compared to the Australian Biotechs industry average (10.1x).
Price to Sales Ratio vs Fair Ratio
What is BIT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 38.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIT's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.